PCSK9 Education and Research Forum:
December 2014
New on PCSK9 Education and Research Forum
Videos from the Inaugural Editorial Board Meeting:
State-of-the-Art PCSK9 Science:
Current understanding and therapeutic perspectives
Familial hypercholesterolaemia: putting the patient first
Katherine Wilemon, CEO of the FH Foundation highlights the invisibility of FH patients and why patient advocacy can make a difference.
‘To improve awareness of FH, we need to involve all players in the FH field, using both top-down and bottom-up approaches’
For more about the FH Foundation: www.thefhfoundation.org
PCSK9 Science
Prof Bertrand Cariou, INSERM UMR1087, l’Institut du Thorax, Nantes, France
Does PCSK9 have effects beyond the liver and if so, what is the evidence?
Prof Anne Tybjaerg-Hansen, Rigshospitalet, Copenhagen University Hospital, and University of Copenhagen, Denmark
Loss of function mutations in PCSK9: the trigger for therapeutic development
Translating Science to the Clinic
Prof Steve Nicholls, South Australian Health and Medical Research Institute and University of Adelaide, Australia
Does PCSK9 inhibition impact atherosclerosis?
Would imaging help to refine clinical management of the high risk patient?
Prof Henry Ginsberg, University of Columbia, New York, USA
PCSK9 and Lp(a), a novel approach to a re-emergent cardiovascular risk factor
Societal Implications: Addressing Unmet Needs in Cholesterol Management
Prof Henry Ginsberg, University of Columbia, New York, USA
What are the patient priorities for PCSK9 inhibitors?
Prof Luis Masana, University Rovira and Virgili, Reus-Tarragona, Spain
High cholesterol: an unmet need
Weighing the cost versus benefit of PCSK9-targeted therapy
Looking ahead with PCSK9 Education & Research Forum
Co-Editor Professor Henry Ginsberg, University of Columbia, New York, USA gives his views
|
|
About PCSK9 Education and Research Forum
|
|
| Send an invitation to join PCSK9 Forum to your colleagues, click here for the invite link |
|
News
Read more news » |
|
|
|
Our mission
Our goal
PCSK9 Education and Research Forum is the major, globally-recognised resource of independent knowledge of PCSK9 science and its translation to therapeutic innovation. Our mission is to facilitate development of these new treatments in order to transform the prognosis of millions of people with hypercholesterolaemia and accelerated atherosclerotic vascular disease.
Our response to this challenge
Established by leading researchers as a not-for-profit organisation, the PCSK9 Education and Research Forum will provide healthcare professionals with open access to electronic and multimedia platforms providing real-time reporting of significant developments and news; authoritative analysis and commentary; and, an extensive library of accredited educational materials tailored to the differing needs of a spectrum of audiences. As a result, the Forum will expand awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.
Our partnership and outreach
Through its unique global network of researchers and clinicians, the PCSK9 Education and Research Forum will reach out to academic institutions, research organisations and societies which share the Forum’s commitment to the reduction of CVD mortality and morbidity through improved management of atherosclerotic dyslipidaemia. The Forum will establish educational partnerships with such organisations through jointly sponsored symposia as well as accredited research and educational programmes. |
|
